Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate
Open Access
- 13 March 2019
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 14 (1) , 1-11
Abstract
Acquired angioedema due to C1-inhibitor (C1-INH) deficiency (AAE-C1-INH) is a serious condition that may result in life-threatening asphyxiation due to laryngeal edema. It is associated with malignant B-cell lymphoma and other disorders. The purpose of this study was to describe the characteristics and associated disorders of patients with AAE-C1-INH and assess the efficacy of plasma-derived C1-INH concentrate (pdC1-INH) in the treatment of AAE-C1-INH. Forty-four patients with AAE-C1-INH from the Angioedema Outpatient Service of Mainz were assessed for associated disorders. In 32 of these patients, the duration of swelling attacks was measured before and after treatment with pdC1-INH (Berinert® (CSL Behring, Marburg, Germany)). The time between injection and complete resolution of symptoms and treatment effectiveness was provided by the patients. The following underlying disorders were present: monoclonal gammopathy of undetermined significance (47.7%), non-Hodgkin lymphoma (27.3%), anti-C1-INH autoantibodies alone (11.4%), and other conditions (4.5%). In 9.1% patients, no associated disorder could be found. AAE-C1-INH led to the detection of lymphoma in 75% of patients with the malignancy. Treatment with pdC1-INH shortened attacks by an average (SD) 54.4 (± 32.8) hours (P < 0.0001). The earlier the attack was treated, the shorter the time between injection and resolution of symptoms (P = 0.0149). A total of 3553 (97.7%) of the 3636 attacks were effectively treated with pdC1-INH as assessed by the patient. The mean (SD) dose per-attack was 787 (± 442) U. pdC1-INH was effective in 1246 (93.8%) of 1329 attacks in 8 patients with anti-C1-INH autoantibodies and in 344 (99.4%) of 346 attacks in 6 patients without autoantibodies. The average (SD) dose per effectively treated attack was 1238.4 (± 578.2) U in patients with anti-C1-INH autoantibodies and 510.2 (± 69.1) U in patients without autoantibodies. pdC1-INH is highly effective in treating AAE-C1-INH patients and is also effective in the vast majority of attacks in patients with anti-C1-INH autoantibodies. It is fast-acting and reduces attack duration.Keywords
Funding Information
- CSL Behring (Educational grant)
This publication has 27 references indexed in Scilit:
- Acquired Angioedema - Occurrence, Clinical Features and Associated Disorders in a Danish Nationwide Patient CohortInternational Archives of Allergy and Immunology, 2013
- International consensus on hereditary and acquired angioedemaAnnals of Allergy, Asthma & Immunology, 2012
- Acquired angioedemaAllergy, Asthma & Clinical Immunology, 2010
- Hereditary angioedema caused by missense mutations in the factor XII gene: Clinical features, trigger factors, and therapyJournal of Allergy and Clinical Immunology, 2009
- Hereditary Angioedema: New Findings Concerning Symptoms, Affected Organs, and CourseThe American Journal of Medicine, 2006
- Relevance of lymphoproliferative disorders and of anti-C1 inhibitor autoantibodies in acquired angio-oedemaClinical and Experimental Immunology, 1996
- An autoantibody to Cl-inhibitor recognizes the reactive center of the inhibitorJournal of Laboratory and Clinical Medicine, 1996
- Acquired C1 inhibitor (C1-INH) deficiency type II. Replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1-INH autoantibodies.Journal of Clinical Investigation, 1989
- Autoantibody-Mediated Acquired Deficiency of C1 InhibitorNew England Journal of Medicine, 1987
- An IgG autoantibody which inactivates C1¯-inhibitorNature, 1986